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By the last half of the 1960s, clinical scientists and administrators were 
agreed that pharmacologic intervention in hypertension had progressed through 
its developmental stages. A number of relatively safe and individually effective 
drugs had been developed--effective in the sense that they produced a substan- 
tial and relatively consistent reduction of blood pressure in hypertensive patients. 
These conclusions had been established through animal studies, small human 
trials, and larger controlled studies in individual clinics and laboratories. 
It remained to be shown, however, that intervention with blood-pressure- 
lowering drugs could reduce the major late effects of hypertension: premature 
mortality and increased risk of cerebral vascular disease, congestive heart failure, 
and renal disease. That elevated blood pressure carried with it the hazard of 
such late consequences had been well established from actuarial statistics, from 
longitudinal community surveys, and from clinical observation. There was a 
strong presumption that drug treatment was effective in this respect, but no 
proof. Clinicians were beginning to comment upon the disappearance of malig- 
nant hypertension, for example. 
The United States Veterans Administration, with its network of medical care 
facilities extending across the U.S.A., had a long history of success in the design 
and conduct of cooperative, multicenter clinical trials, dating from its landmark 
investigations of chemotherapy for pulmonary tuberculosis. The VA's relatively 
tight administrative apparatus made it a natural locus for such development. 
Its Cooperative Studies Evaluation Committee provided a central review mecha- 
nism applicable to a broad array of proposed studies. Thus, it was natural that 
the Veterans Administration would decide to establish a tightly designed, con- 
trolled, multicenter trial of the late effects of antihypertensive medication. 
Dr. Edward Freis assumed major responsibility for the organization and develop- 
ment of protocols, and the applications passed internal review. The rest is 
history. Scientists will be discussing the results of this landmark investigation 
for years to come. The trials established that combination therapy for moderate 
and severe hypertension produced a substantial reduction in all-cause mortality 
and major morbidity, at least in middle-aged male U.S. war veterans. Remain- 
ing at issue were the effects in women, in mild hypertensives, and in less highly 
selected segments of the population. Furthermore, effects on coronary heart 
disease were unclear and remain controversial. 
At a critical stage in this history, a decision had been made that the coopera- 
tive, multicenter clinical trial was the investigative tool of choice for answering 
an important question. Why and how are such decisions made? Although the 
Veterans Administration, the National Cancer Institute, the National Heart 
Institute, the armed forces, and other groups here and abroad had developed 
and applied this methodology in the 195Os, to this date little attention has been 
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given to the important public policy issues involved. Such trials are expensive. 
They demand substantial financial resources. They preempt the skills and 
energies of large numbers of investigators over relatively long periods of time. 
They require attention to a central theme, protocol, and detailed manual of 
operations, thereby placing constraints on individual investigative initiative. 
They are highly visible, in success and failure. They can produce conclusions 
or controversies, the latter sometimes extending over a period longer than that 
required to conduct the trial itself. Agencies, legislative bodies, and the general 
public need a better specification of the public policy issues involved in the 
decision to invest in such major undertakings. 
At a minimum, a cooperative trial should not be launched in the absence 
of a substantial question of therapy or intervention. While many of us would 
agree with Dr. Chalmers’ admonition that we should “randomize the first case,” 
reminding us that as therapeutic habit becomes entrenched, it is more and more 
difficult to conduct valid scientific evaluation, this admonition does not apply 
to the cooperative, multicenter trial. Before such a trial is seriously contem- 
plated, we should find ourselves at a therapeutic crossroads. Our need to know 
the efficacy and safety of a particular mode of intervention should be acute 
and should be impeding further scientific advance. It should be clear that a 
positive versus a negative answer would result in a marked change in investiga- 
tive direction and therapeutic management of the typical patient. Major ethical 
issues should have been solved and the treatment should be acceptable for 
patient management. 
The cooperative multicenter trial provides the opportunity to reach an 
answer to a substantive clinical question over a reduced period of time. Pooling 
of resources makes possible the enrollment of larger numbers of patients than 
could occur within any single clinical setting. While standardization and 
uniformity of approach are essential, conduct of therapeutic investigations in 
a variety of settings broadens the scope of scientific inferences. The involve- 
ment of a number of investigators working toward answers to the same ques- 
tions strengthens the likelihood of a favorable result, while diminishing the 
opportunity for oversight and error. Nevertheless, this multiplicity of investiga- 
tors also produces an averaging effect resulting from negotiation and com- 
promise. Thus, the cooperative trial becomes a relatively blunt instrument, 
most appropriate for answering broad rather than highly detailed questions. 
While disease mechanisms may be elucidated in such trials, these results most 
often flow from ancillary studies off the main stream of the cooperative investi- 
gation. Finally, a collaborative trial should probably be contemplated only 
when investigating a disease process with major sequelae such as mortality or 
major morbidity. 
How many cooperative, multicenter trials are needed? This question cannot 
be answered in any detail because of the public policy hiatus noted earlier. Will 
the conduct of such trials act as a stimulus or as a deterrent to other biomedical 
research? Is the “full bucket” model, which assumes a stable number of dollars 
for the entire national health research effort, appropriate? This model states 
that allocation of a major number of dollars for one purpose results in fewer 
dollars for other purposes. Does such research have a stultifying effect on 
investigative initiative? Does such research constitute bureaucratic “targeting” 
in which investigators have little or no role in following scientific leads of their 
own? Or alternatively, does such research have a stimulating effect on the 
entire national biomedical research effort, increasing public awareness and, in 
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turn, producing a greater emphasis upon this sector of the national economy? 
Do agencies adequately involve broad scientific opinion before launching such 
investigations and in their design? Do such investigations attract young people 
who might otherwise devote themselves entirely to the private practice of medi- 
cine? It seems curious that these important issues have received so little syste- 
matic attention. 
What is the cooperative multicenter trial? First of all, it is a substantial 
scientific question demanding a relatively rapid answer in a variety of settings. 
In addition, it is an organization, a group of people and facilities oriented 
toward a common goal. Here, I will attempt to describe a minimal organiza- 
tional pattern. Specific trials may require additional organizational components. 
A senior operating or executive committee, composed of investigators with 
a direct stake in the research, is essential. These individuals should be em- 
powered, within broad limits established by the funding agency, to make operat- 
ing decisions. While agency and other outside individuals may be members of 
this body, its primaiy focus should be on getting the work done, and, therefore, 
its primary membership should be workers. 
A coordinating and data-collecting center should be established. In some 
trials, administrative coordination and data storage and maintenance are sepa- 
rated in two locations. However, all study data should eventually arrive at a 
central point for editing, storage, retrieval, monitoring, and analysis. At this 
coordinating center, senior statistical and data-processing personnel should be 
available. This unit will be the sensory apparatus of the study, determining 
that the agreed upon goals and detailed operating procedures are being followed 
uniformly. The center will have multiple reporting responsibilities. For primary 
operational considerations, it will report to the steering or executive committee, 
but it will also bear responsibilities directly to the funding agency and to moni- 
toring bodies. 
A group of clinical centers, directed by strong individuals who nevertheless 
agree to pursue common objectives using common methods is essential to the 
success of any cooperative trial. At each center, the principal investigator will 
be responsible for producing a set of observations that can be pooled with 
similar data from other centers. He or she will be responsible for recruiting 
an adequate number of patients, for supervising local personnel, and for 
operating the study in a manner consistent with agreed procedures. 
Standardization is essential, and the opportunity for lack of standardization 
multiplies as the number of clinical centers increases. Biochemical observations 
should be controlled through the use of blinded reference laboratory techniques. 
Often, a central biochemical laboratory will be used to receive specimens, to 
produce individual determinations, and to certify through external monitoring 
the accuracy of its own methods. In addition, clinical observations such as 
electrocardiograms and x-ray readings may require central control facilities. 
A cooperative trial requires an external data monitoring and review struc- 
ture, i.e., a mechanism for accountability. This monitoring group should deter- 
mine that toxic or other adverse effects are being carefully watched and are 
controlled within acceptable limits. This body should also review endpoint data 
to determine whether the trial should be stopped prematurely, either for ethical 
or scientific reasons. This committee will report directly to the funding agency, 
which of course has final authority to stop the flow of funds. The committee 
will receive appropriate data from the coordinating center, creating another 
organizational link. Conclusion of any trial is a difficult matter and a variety 
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of technologies must be brought to bear. These include formal statistical 
methodology, sometimes sequential or quasi-sequential in character and some- 
times based on a fixed sample size. Other components of a stopping rule include 
ethical issues, issues of relationship between the study and the community in 
which it is being conducted, and issues of extension of the study beyond the 
planned completion date. 
A number of specific design features must be agreed upon before the study 
is initiated. This will require a planning or pilot phase in which field testing 
of proposed, questionnaires and investigative methods can be conducted. In the 
case of the Hypertension Detection and Follow-up Program, this period included 
a decision whether to use an automated blood pressure measuring device. In 
addition, sample size must be determined and the procedures for data flow 
completely specified. 
Determination of sample size in a scientifically defensible manner is essential 
before the study gets under way. If the trial is to involve a fixed sample size 
rather than a purely sequential design (the latter a relative rarity among co- 
operative therapeutic trials), then several issues are at stake. A primary end- 
point or endpoints must be established for design purposes. The frequency of 
this endpoint in the control or comparison group should be estimated. The 
amount of effect on the primary endpoint as a result of treatment should be 
considered carefully. The investigators should decide how large an effect would 
be important to the subsequent scientific history of management of the disease. 
For example, would a 25% reduction in mortality be important and worth 
pursuing? Operating probability levels should then be determined: the level of 
significance or probability of finding a difference of the desired magnitude when, 
in fact, no such difference exists in the population from which the patients are 
drawn, and the power of the investigation, i.e., the probability of detecting a 
true difference of the magnitude specified. In addition, the dilution effect of 
loss to follow-up or other inability to determine endpoints should be estimated. 
The greater the dilution, the greater the sample size. It should be decided 
whether separate subdesigns for efficacy and safety will be used. In some in- 
stances, it may be possible to design a quasi-sequential scheme for detecting 
adverse effects. In this event, however, many of the same decisions concerning 
event frequency and operating probability levels must be made. 
Thrcughout this discussion, we have assumed that patients will be allocated 
to one of several groups, differentiated by treatment status. In the classical 
trial, patients receive either active drugs or apparently identical but inactive 
placebo medication, the allocation of patient to specific group being at random, 
i.e., with the use of a table of random numbers. Randomization and monitoring 
to see that such randomization has been adequately completed is the responsi- 
bility of the statistical coordinating center. In the classical trial, patients and 
physicians are blinded with respect to the specific treatment group. Provision 
is made for breaking the blind for reasons of patient safety according to a 
standard set of provisions described in the manual of operations. 
Advanced planning for the cooperative trial is relatively more important 
than for the single-center study. Objectives must be relatively fully specified 
and priorities among those objectives rigidly set. While one or more endpoints 
may be classified as major design endpoints, other outcome measures will ordi- 
narily also be investigated. Assessment of all endpoints in as objective and 
reproducible a manner as possible is critical to the successful outcome of the 
study. It is important, wherever possible, to specify hypotheses concerning 
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outcomes in patient subgroups in advance of the trial. Strong and largely 
unsolvable statistical problems exist if an attempt is made to “dredge” data at 
the conclusion of the study, in the absence of advanced specification of prob- 
lems of interest. This is not to say that incomplete data analysis is desirable. 
However, the investment in a cooperative trial makes it mandatory to specify 
scientific questions in advance in order that findings will be dependable. 
Because a trial is so costly, it is desirable, whenever feasible, and without 
compromising the major objectives of the trial, to seek to accomplish multiple 
purposes. Although, as noted earlier, the cooperative trial is a relatively blunt 
investigative tool, this bluntness is no excuse for failing to realize the maximum 
potential from a large investment. The initial pilot phase can assist in maximiz- 
ing study potential. 
The collaborative trial requires cooperation on a wide variety of levels. 
Individual investigators must to some degree subjugate their own initiative to 
the demands of the design. Workers from different disciplines-clinical, epi- 
demiologic, statistical-must all collaborate, sharing their special expertise in 
the conduct of the trial. While democratic processes are essential to make sure 
that every voice is heard, a final decision-making apparatus is necessary in order 
that the study may proceed smoothly toward its conclusion. The objectives of 
any such trial are primarily in the area of patient management and care. If 
experienced statisticians and computer technologists are available, there is 
seldom a reason for conflict between the quantitative demands of design and 
analysis and the reasonable desires of the clinical investigators. Trial ethics is a 
highly individualized matter, and investigators active in the trial must be con- 
vinced that they are embarked on a fully defensible ethical course. 
Because of the ponderous nature of a clinical trial and the amount of inertia 
and momentum it develops, it is a relatively poor vehicle for major technical 
innovation in data processing or management. Such innovation has in the past 
occasionally produced unconscionable delays in releasing the data trapped inside 
large computer files. Again, the primary objective of such a trial is the improve- 
ment of our understanding of a therapeutic or intervention process, and technical 
or manipulative aspects must not interfere with this objective. Even so, when 
placed in proper perspective, such trials can and should provide important 
insights into improved data-management techniques for subsequent trials. In 
addition, the professional interests of statisticians and computer scientists must 
be recognized if high quality collaboration is to be expected. Ancillary technical 
studies can be helpful in this regard. 
One of the administrative challenges of such investigations is the amount 
of “academic credit” available to investigators devoting a substantial portion 
of time to the study. Publications will often be produced at a relatively slow 
rate during the course of a cooperative trial, although it is important to plan 
the publication program concurrently with initiation of the trial. Rights of 
authorship and individual citation are important to individuals, particularly 
young scientists whose future is at stake. The devotion of a young scientist’s 
full-time activity to collaborative research seems questionable, because of pre- 
vailing attitudes of administrators and faculty peers considering promotion and 
advancement. These are examples of administrative problems attendant to the 
management of clinical trials. Too often, a trial is begun without careful con- 
sideration of such issues. 
In many respects, the most difficult part of collaborative research is ending it. 
There always seems to be just one more question that could be answered. It 
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seems a terrible waste to dismantle an efficiently functioning administrative 
structure. For this reason, cooperative trials tend to end with a whimper rather 
than a bang, or like old soldiers, simply fade away. As we move into trials 
involving direct participation by community groups and direct intervention into 
the public health, we can expect even more problems in phasing out such studies. 
When an improved process for delivering health care to the population is estab- 
lished as the result of a trial, particularly difficult questions of discontinuing 
delivery of that improved process to participants arise. While we have not 
completely solved such problems, it is important to involve community groups, 
investigators, and the funding agency in such considerations from the beginning 
of the program. Abrupt withdrawal of an effective mode of intervention will 
leave justifiably angry people and communities in the wake of the study. 
Finally, the trial must end with an intellectual question mark. It should 
pose this question mark as carefully as possible in order that other investigators 
in other places can pick up the investigative thread and continue progress toward 
full understanding of the disease process and its management. While that 
distant goal will probably never be reached, the cooperative trial has a particular 
investigative obligation strongly to suggest next steps. 
Not every question requires cooperative study methodology. However, as 
we develop a variety of safe and effective treatments, we can expect more and 
more cooperative trials, particularly ones designed to improve delivery of im- 
proved care to the general public. In this latter area, we are truly in our infancy, 
but trials like the Hypertension Detection and Follow-up Program constitute 
important first efforts. As we move into these areas of direct concern for the 
public health and its improvement, we can expect the public policy questions 
mentioned earlier to increase in importance. We should move promptly to 
establish a dialogue leading to an operating consensus on these issues. 
